Podcasts about sanofi aventis

This episode covers: Cardiology This Week: A concise summary of recent studies The role of cardiac magnetic resonance in myocardial disease Air pollution and heart disease Statistics Made Easy: Quasi-experimental study designs Host: Rick Grobbee Guests: Carlos Aguiar, Steffen Petersen, Mark Miller Want to watch that episode? Go to: https://esc365.escardio.org/event/1806 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee, Nicolle Kraenkel and Mark Miller have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Steffen Petersen Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1806?r Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Colchicine for secondary prevention An algorithmic approach to the workup of syncope Milestones: CIBIS II Host: Rick Grobbee Guests: Carlos Aguiar, Sanjit Jolly, Michele Brignole Want to watch that episode? Go to: https://esc365.escardio.org/event/1805 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Sanjit Jolly has declared to have potential conflicts of interest to report: grant support from Boston Scientific, honorarium from Boston Scientific, Shockwave, Abiomed, SIS, and Teleflex.  Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Rick Grobbee Guest: Michele Brignole Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1805?r  Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Michele Brignole, Diederick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Hypertension in the elderly The digital twin in cardiology Snapshots Host: Emer Joyce Guests: Carlos Aguiar, Gianfranco Parati, Nico Bruining, Joost Lumens Want to watch that episode? Go to: https://esc365.escardio.org/event/1804 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Gianfranco Parati has declared to have potential conflicts of interest to report: honoraria for lectures by Omron, Merck, Viatris, Somnomedics. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guests: Joost Lumens and Nico Bruining Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1804?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.  Declarations of interests: Stephan Achenbach, Nico Bruining, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Joost Lumens has declared to have potential conflicts of interest to report: research grants from Medtronic (all grants paid to institute, Maastricht University). Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Current indications for pulmonary vein isolation Conduction system pacing EHRA 2025 scientific highlights Host: Susanna Price Guests: Haran Burri, Isabel Deisenhofer, Helmut Puererfellner, Emma Svennberg Want to watch that episode? Go to: https://esc365.escardio.org/event/1803   Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Haran Burri has declared to have potential conflicts of interest to report: institutional research and fellowship support or speaker honoraria from Abbott, Biotronik, Boston Scientific, Medtronic, Microport. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Helmut Puererfellner has declared to have potential conflicts of interest to report: speaker fees, honoraria, consultancy, advisory board fees, investigator, committee member, etc., including travel funding related to these activities for the following companies: Abbott, Biotronik, Biosense Webster, Boston Scientific, Daiichi Sankyo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price  Guest: Thomas Deneke  Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1802?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Thomas Deneke, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Relevance and management of ventricular ectopic beats  Lp(a) in cardiovascular risk management Mythbusters: A vegetarian diet lowers cardiovascular risk Host: Susanna Price Guests: Carlos Aguiar, Thomas Deneke, Kausik Ray Want to watch that episode? Go to: https://esc365.escardio.org/event/1802 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Thomas Deneke, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Kausik Ray declared to have potential conflicts of interest to report: research grants from Amarin, Amgen, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Regeneron, and Sanofi, consultant for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Biologix, Boehringer Ingelheim, Cargene Therapeutics, CRISPR, CSL Behring, Eli Lilly and Company, Esperion, Kowa Pharmaceuticals, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Silence Therapeutics, Vaxxinity, and Viatris, honoraria for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Biologix Pharma, Sanofi, Amgen, Esperion, Daiichi Sankyo, Macleod and stock options New Amsterdam Pharma, Pemi 31, SCRIBE Therapeutics. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: Maya Buch Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1801?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Maya Buch has declared to have potential conflicts of interest to report: grant/research support paid to University of Manchester from Gilead and Galapagos; consultant and/or speaker with funds paid to University of Manchester for AbbVie, Boehringer Ingelheim, CESAS Medical, Eli Lilly, Galapagos, Gilead Sciences, Medistream and Pfizer Inc; member of the Speakers' Bureau for AbbVie with funds paid to University of Manchester. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies AI and the future of the Electrocardiogram The heart in rheumatic disorders and autoimmune diseases Statistics Made Easy: Bayesian analysis Host: Susanna Price Guests: Carlos Aguiar, Paul Friedman, Maya Buch  Want to watch that episode? Go to: https://esc365.escardio.org/event/1801 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Antonio Greco, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Maya Buch has declared to have potential conflicts of interest to report: grant/research support paid to University of Manchester from Gilead and Galapagos; consultant and/or speaker with funds paid to University of Manchester for AbbVie, Boehringer Ingelheim, CESAS Medical, Eli Lilly, Galapagos, Gilead Sciences, Medistream and Pfizer Inc; member of the Speakers' Bureau for AbbVie with funds paid to University of Manchester. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Paul Friedman has declared to have potential conflicts of interest to report: co-inventor of AI ECG algorithms. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Join Prof. Lisa Beck as she explores the chronic and persistent burden of AD as well as the concept of early intervention.   ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits.   Speaker disclosures: Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.    © 2025 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2407353  – 1.0 – 02/2025 MAT-US-2501683 v1.0 - P Expiration Date: 02/24/2027

This episode covers: Cardiology This Week: A concise summary of recent studies Non-bacterial thrombotic endocarditis Managing cardiovascular risk in transgender people Milestones: RAVEL Host: Perry Elliott Guests: Kyle Klarich, Christian Delles Want to watch that episode? Go to: https://esc365.escardio.org/event/1800 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor.  This programme is intended for health care professionals only and is to be used for educational purposes.  The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Christian Delles, Kyle Klarich and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Perry Elliott Guest: Christian Delles Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1800?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Christian Delles and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Atrial fibrillation in athletes 'Work and life' of a medical journalist Mythbusters: Female doctors with better outcomes Host: Perry Elliott Guests: Carlos Aguiar, Isabelle van Gelder, Shelley Wood Want to watch that episode? Go to: https://esc365.escardio.org/event/1799   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests  Stephan Achenbach, Nicolle Kraenkel, Isabelle van Gelder and Shelley Wood have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Perry Elliott Guest: Isabelle van Gelder Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1799?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Isabelle van Gelder have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Dual antiplatelet therapy in 2025 Optimal communication with patients Snapshots Host: Emer Joyce  Guests: Carlos Aguiar, Michelle Kittleson, Gilles Montalescot Want to watch that episode? Go to: https://esc365.escardio.org/event/1798   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Emer Joyce, Michelle Kittleson and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Gilles Montalescot Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1798?resource=interview   Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Gilles Montalescot has declared to have potential conflicts of interest to report: research funds for Action Groupe or honoraria from Abbott, Amgen, AstraZeneca, Bayer, BMS, Boehringer-Ingelheim, Celecor, CSL Behring, Hexacath, Idorsia, Lilly, Novo Nordisk, Pfizer, SMT, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Coronary spasm management Sex differences in heart failure Milestones: London Bus Driver Host: Emer Joyce Guests: Filippo Crea, Lynne Stevenson Want to watch that episode? Go to: https://esc365.escardio.org/event/1797 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Filippo Crea, Emer Joyce, Nicolle Kraenkel and Lynne Stevenson have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Emer Joyce Guest: Filippo Crea Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1797?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Filippo Crea, Emer Joyce and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In der letzten Episode der Grippeschutz-Reihe geht es um Risikogruppen. Wer ist besonders betroffen, wer hat ein hohes Risiko für schwere Verläufe und wer sollte sich unbedingt impfen lassen? Darüber diskutieren wir wieder mit unseren zwei Expertinnen Frau Dr. Sandow und Dr. Lucas. Hören Sie rein und erweitern Sie Ihr Fachwissen!

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Hypertensive disorders during pregnancy Depression and heart disease Mythbusters: "The French Paradox" Host: Perry Elliott Guests: Carlos Aguiar, Martha Gulati, Hector Bueno Want to watch that episode? Go to: https://esc365.escardio.org/event/1796 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Martha Gulati, Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Hector Bueno has declared to have potential conflicts of interest to report: research funding from the European Union (EU4H-2022-JA-03), Instituto de Salud Carlos III, Spain (FORTALECE program, PI21/01572), Sociedad Española de Cardiología, AstraZeneca, Boehringer Ingelheim, Janssen, and Novartis; and has received in the past consulting/speaking fees from Astra-Zeneca, Novartis, Novo Nordisk and Organon. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.  This episode covers: Cardiology This Week: A concise summary of recent studies Aortic aneurysms Return to elite sports after a severe cardiac event Milestones: CAST Host: Emer Joyce Guests: Carlos Aguiar, Jose Rodriguez Palomares, Harald Jorstad Want to watch that episode? Go to: https://esc365.escardio.org/event/1795 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Emer Joyce, Nicolle Kraenkel and Jose Rodriguez Palomares have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Harald Jorstad has declared to have potential conflicts of interest to report: unrestricted research grants to institution: Dutch Olympic Committee, Dutch Heart Foundation, Zon-Mw, Heart to Handle. Unrestricted, unrelated research grants to institution: Novartis, Amarin, Novo Nordisk, Sanofi. Unrelated advisory fees to institution: Amarin, Amgen. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In der zweiten Episode der Grippeschutz-Reihe geht es um die Impfquote. Diese ist in Deutschland weit entfernt vom WHO-Ziel von 75% in besonders gefährdeten Personengruppen. Wie Apotheken eine Chance bieten können, die Impfrate in Deutschland zu steigern, darüber sprechen wir wieder mit unseren zwei Expertinnen Frau Dr. Sandow und Dr. Lucas. Hören Sie rein und erweitern Sie Ihr Fachwissen!

David Miller kicks off the conversation with a summary of his life since Harvard. He went to Brown University, Providence, and then moved back to Boston, where he spent five years in Cambridge, Somerville, Arlington, and then moved to Santa Monica, California, where his wife was pursuing her fellowship. He then returned to Boston, where he has been for 20 years, minus a three-month stint in Paris, France. Technology Inventor,  Independent Contributor, and Instructor David met his wife, Ruth Herzman Miller, in October of his freshman year at Harvard. They have three daughters, and David has spent some time as a full-time dad with each of them. He majored in mathematics at Harvard and pure mathematics at graduate school at Brown. After a pause, he worked in speech and language processing at Bolt, Beranek and Newman (BBN) Technologies in Cambridge where he worked on developing speech to text transcription and information retrieval. He went to UCLA to learn bioinformatics and worked at a bioinformatics laboratory at the Molecular Biology Institute. In 2001, he returned to Boston and worked at Aventis Pharmaceuticals, now Sanofi Aventis, applying his knowledge in lead generation informatics. He stayed at Aventis for a few years before taking some time off the workforce. In 2008, David joined Google for 16 years, primarily on the search engine. He has worked on various projects, including the Google Books project and AI Overviews. He has also spent time at Google Paris, Zurich, and Tokyo. He has also taught computer science in the context of the Girls Who Code Project, where he distributed curriculum material to numerous chapters and hosted meetups. He also worked with Microsoft TEALS (technology and learning in schools), teaching ninth and 10th grade computer science. Inspired by French Theater  During the pandemic, revisited an interest he had discovered in Paris, French theater. He started studying French and learned about the annual Theater Festival in Avignon, France, which is the second largest Fringe Festival in the world. After visiting the festival in 2022, he decided to create a similar event in Boston. He started a limited liability corporation with knowledge of French, Boston theater scene, organizational capacity, and spare finance. The first production was performed in April 2024, and the second is set to open in November 2024. They are currently booking venues and signing contracts for their 2025-2026 season.  Google, AI, and The BERT Revolution The conversation turns to  AI, BERT, and Google. He explains that the feature of BERT was built to transform language problems into arithmetic problems, using embeddings in high-dimensional vector spaces to catch semantics. This allowed for more complex arithmetic than just adding and subtracting. The BERT Revolution, invented by Jacob Devlin and his colleagues, was used to map words to embeddings, allowing for real-world correspondence in arithmetic. This concept was later used in Google's Featured Snippets, which was revamped to use embeddings and the Bert revolution. David's lecture at Boston University, which is titled "Natural Language Understanding, Deep Learning and the BERT Revolution" discusses the underlying mechanics of natural language processing and how it transformed problems in language into arithmetic. The BERT Revolution allowed for more complex arithmetic than just adding and subtracting, making it easier for neural networks to perform complex tasks.  The Rise of Hidden Markov Models David talks about the state-of-the-art technology at the time, Hidden Markov models, which had a temporal aspect of a changing probability distribution. These models were based on the sequence of text, and the Bayesian reasoning was used to determine the most likely audio to come from the words. This led to the development of generative models, where words generate the audio through probabilistic models. However, Bayesian modeling has been replaced by deep neural nets in the last five years of generative AI. He mentions that, in the early days, neural networks were untrainable and unwieldy, making Hidden Markov models the Bayesian generative approach. However, deep neural networks are now used. The Development of Neural Networks David discusses the development of neural networks, a technology that has been around since the 1950s. The availability of more recordings for speech, text, and language models has made it more accessible on the hardware side. The core of a neural network computation is matrix multiplication, which has been addressed by Nvidia and Google with their TensorFlow units. These units have invested large amounts of money in making specialized, custom hardware for this problem, accelerating things. David talks about how algorithms have also advanced significantly since the 1950s, and mentions key factors that have aided the advancement.    Becoming an Individual Contributor at Google David talks about how he learned the technology. He decided to become an individual contributor and studied the technology, the code, the papers, books, videos, and experiments. He spent most of the pandemic working on neural nets that eventually became the Gemini technology. David's journey to becoming a knowledgeable and skilled individual in neural networks was a journey that took him from a theoretical interest to a practical application. He learned to make the most of the technology and its capabilities, ultimately contributing to the advancement of the field. David has faced mixed reactions to his decision to become an independent contributor at Google. While some were supportive and skeptical, others were skeptical. He talks about the advice he received, how he moved forward, the success rate of his projects, and how his career has decelerated since 2019.  Behind the Curtain of French Theater The discussion moves to French theater and how David has become a French theater producer. He shares his journey of starting a production in Boston from scratch. To start a French theater production in Boston, David had to be integrated into the French community in Boston and the theater community in Boston. They do not create the theater but bring the original production to Boston and add subtitles. He talks about the challenges faced in securing locations, staff and equipment, and managing the production process such as hiring a director, actors, space, marketing, and logistics. He uses services like Playbill to manage administration, program design, publicity, and logistics. He is passionate about creating a new cultural institution in Boston that focuses on French theater. Boston is known for its strong ties to France and hospitals, and David aims to create a French theater festival or translate French theater into English. He works with the French American Chamber of Commerce of New England, which helps create businesses and connections in Boston. Behind the Screen of Girls Who Code David has worked with Girls Who Code, an after-school program that runs programs for young women interested in programming and technology. He organized a meet-up at Google's Cambridge office, where he gave a keynote speech at parent meetings, emphasizing the importance of belonging and ownership in the industry. He was able to connect with 150 teenage girls and their parents, who expressed gratitude for his message. David's involvement with Girls Who Code has led to a sense of belonging and empowerment for these young women, who are now more likely to pursue careers in the tech industry. He believes that the French language theater in Boston could potentially sustain them through a 25-year career in the industry. Influential Harvard Professors and Courses David shares his experiences as a TA in the math department and working with Deborah Hughes Hallet, who was running a calculus project. David's theater experience has played an ongoing role in his teaching approach, as he learned from her dedication and approach to teaching. He believes that the notion of understanding the world through teaching is a deep-rooted belief in his approach.  Timestamps: 03:59: Professional Career and Industry Experience  06:52: Non-Professional Activities and Community Involvement  11:22: Technological Advancements and AI Overview  25:07: Transition to Individual Contributor Role at Google  30:17: French Theater Project and Community Building 40:39: Impact of Girls Who Code and Teaching  45:25: Final Thoughts and Contact Information  Links: Theater: www.frenchtheaterproject.com Theater Club: https://frenchlibrary.org/french-library-theater-club/ Website: www.monsieurmiller.com LinkedIn: https://www.linkedin.com/in/davidrhmiller/ David's  2019 lecture "Natural Language Understanding, Deep Learning and the BERT Revolution" at Boston University : https://www.youtube.com/watch?v=DktFhgxynFE Featured Non-profit This week's featured non-profit is the Cure San Filippo Foundation recommended by Adam Shaywitz who reports: “Hi. I'm Adam Shaywitz, class of 1992 the featured nonprofit of this episode of The 92 report is the Cure San Filippo Foundation. This organization is dedicated to advancing treatment options for children affected by the devastating childhood dementia known as San Filippo syndrome. I am privileged to serve as a board member for the past five years. You can learn more about their work at Cure Sanfilippo foundation.org, that's one word. Cure Sanfilippo foundation. San Felippo is spelled s, a, n, f, i, L, i, p, p, O, that's 1f, 1l, and 2p Cure San Filippo foundation.org, and now here is Will Bachman with this week's episode.” To learn more about their work visit: www.CureSanFilippoFoundation.org.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.  This episode covers: Cardiology This Week: A concise summary of recent studies Heart disease in dialysis patients Substance abuse and heart disease Snapshots: Pneumopericardium Host: Emer Joyce Guests: Carlos Aguiar, Patrick Mark, Theo Pezel, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/1794 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Emer Joyce, Nicolle Kraenkel and Theo Pezel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Patrick Mark has declared to have potential conflicts of interest to report: lecture/advisory board honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Pharmacosmos, Astellas, GSK, Vifor. Grants from Boehringer Ingelheim, AstraZeneca. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Optimal management of angina Artificial sweeteners and cardiovascular risk Statistics Made Easy: Network meta-analyses Host: Perry Elliott Guests: Carlos Aguiar, Christiaan Vrints, Marco Witkowski Want to watch that episode? Go to: https://esc365.escardio.org/event/1793 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Antonio Greco, Nicolle Kraenkel, Christiaan Vrints and Marco Witkowski have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In der ersten Episode der Reihe zum Thema „Grippeschutz“ geht es um die neuesten Erkenntnisse zur Grippeschutzimpfung. Wie diagnostiziert man eine Influenza präzise und wie effektiv ist die Impfung in der Praxis? Zwei Expertinnen teilen Einblicke und praxisnahe Empfehlungen für die kommende Grippesaison. Hören Sie rein und erweitern Sie Ihr Fachwissen!

Join Dr. Mario Castro and Prof. Vibeke Backer as they discuss airway remodeling and airway hyperresponsiveness and their impact in the lives of patients with severe asthma. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com.   This podcast is intended for healthcare professionals only.   Disclaimer: This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program. The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits. Speaker disclosures: Mario Castro, MD, MPH, reports grants and research support from NIH, ALA, PCORI, AstraZeneca, Gala Therapeutics, Genentech, GSK, Novartis, Pulmatrix, Sanofi-Aventis, Shionogi, and Theravance. He receives consulting fees from Genentech, Teva, Sanofi-Aventis, Merck, Novartis, Arrowhead Pharmaceuticals, Allakos, Amgen, OM Pharma, Pfizer, Pioneering Medicines, and GSK. He receives payment for speaker bureau activities from Amgen, AstraZeneca, Genentech, Regeneron, Sanofi-Aventis, and Teva. He also receives stock options from Aer Therapeutics. Vibeke Backer, MD, has worked as an advisor, supervisor, and investigator of pharmaceutical studies and has received unrestricted grants from AstraZeneca, GSK, MSD & Schering Plough, ALK-Abelló, Nycomed, Chiesi, Novartis, Pharmaxis, Nigaard, Pfizer, Boehringer Ingelheim, Maribo Medico, Aerocrine, Teva, Sanofi, Regeneron, and BIRK NPC. © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401489 – 1.0 – 10/2024 MAT-US-2410093 v1.0 – P Expiration Date: 10/09/2026

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Which MRA to use in which heart failure patient Managing electrical storm Mythbusters: garlic protects from the heart Host: Perry Elliott Guests: Carlos Aguiar, Sana Al-Khatib, Rudolf de Boer Want to watch that episode? Go to: https://esc365.escardio.org/event/1792 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Sana Al-Khatib and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: direct research funding from European Research Council (ERC), Netherlands Heart Foundation, Fondation leDucq, Netherlands Organization for Scientific Research. Research funding to department or institution: AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals GmbH, NovoNordisk. Direct fees from Abbott, AstraZeneca, Cardior Pharmaceuticals GmbH, NovoNordisk, Roche Diagnostics. Fees to department or institution: NovoNordisk. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology this Week: A concise summary of recent studies Strategic decisions in atrial fibrillation Critical evaluation of clinical trials Snapshots Host: Perry Elliott Guests: Stephan Achenbach, Carlos Aguiar, Jane Armitage, Isabel Deisenhofer Want to watch that episode? Go to: https://esc365.escardio.org/event/1720 Disclaimer ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Jane Armitage and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Isabel Deisenhofer has declared to have potential conflicts of interest to report: speaker honoraria and travel grants from Abbott Medical, Biosense-Webster, Boston Scientific, BMS, Volta Medical, and research grant (for the institution) from Abbott Medical and Daiichi Sankyo. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics, AstraZeneca, Forbion. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging, Inc., Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

rWotD Episode 2669: ViroPharma Welcome to Random Wiki of the Day, your journey through Wikipedia’s vast and varied content, one random article at a time.The random article for Saturday, 24 August 2024 is ViroPharma.ViroPharma Incorporated was a pharmaceutical company that developed and sold drugs that addressed serious diseases treated by physician specialists and in hospital settings. The company focused on product development activities on viruses and human disease, including those caused by cytomegalovirus (CMV) and hepatitis C virus (HCV) infections. It was purchased by Shire in 2013, with Shire paying around $4.2 billion for the company in a deal that was finalized in January 2014. ViroPharma was a member of the NASDAQ Biotechnology Index and the S&P 600.The company had strategic relationships with GlaxoSmithKline, Schering-Plough, and Sanofi-Aventis. ViroPharma acquired Lev Pharmaceuticals in a merger in 2008.This recording reflects the Wikipedia text as of 00:01 UTC on Saturday, 24 August 2024.For the full current version of the article, see ViroPharma on Wikipedia.This podcast uses content from Wikipedia under the Creative Commons Attribution-ShareAlike License.Visit our archives at wikioftheday.com and subscribe to stay updated on new episodes.Follow us on Mastodon at @wikioftheday@masto.ai.Also check out Curmudgeon's Corner, a current events podcast.Until next time, I'm neural Matthew.

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention may impact disease course. ADVENT is a medical education non-promotional resource for healthcare professionals organized by Sanofi and Regeneron. Learn more at ADVENTprogram.com. This podcast is intended for healthcare professionals only. Disclaimer:  This program is non-promotional and is sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The speakers are being compensated and/or receiving an honorarium from Sanofi and Regeneron in connection with this program The content contained in this program was jointly developed by the speakers and Sanofi and Regeneron and is not eligible for continuing medical education (CME) credits Speaker disclosures: April Armstrong, MD, MPH has served as a research investigator, scientific advisor, or speaker to AbbVie, Amgen, Almirall, Arcutis, ASLAN, Beiersdorf, BI, BMS, EPI, Incyte, Leo, UCB, Janssen, Lilly, Mindera, Nimbus, Novartis, Ortho, Sun, Dermavant, Dermira, Sanofi, Takeda, Organon, Regeneron, Pfizer and Ventyx Lisa Beck MD, consults for Abbvie, Allakos, Arcutis Biotherapeutics, Arena Pharmaceuticals, Aslan Pharma, Astria Therapeutics, Celldex, Dermavent, DermTech, Escient Pharma, Eli Lilly Company, Evelo Biosciences, Galderma, Incyte, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Numab Therapeutics, Pfizer, Proteologix, Rapt Therapeutics, Regeneron, Ribon Therapeutics, Sanofi/Genzyme, Sanofi-Aventis, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, Union Therapeutics, Xencor and Yuhan and has been an Investigator for Abbvie, Astra-Zeneca, DermTech, Kiniksa, Pfizer, Regeneron, Ribon Therapeutics and Sanofi.  © 2024 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-GLB-2401395 - 1.0 - 07/2024 MAT-US-2407636 v1.0 - P Exp Date: 07/31/2026

This is the Weight and Healthcare newsletter! If you like what you are reading, please consider subscribing and/or sharing!Reader Shauna asked “I just saw an article about the Body Roundness Index, is that as silly as I think it is?”The Body Roundness Index seems to be the weight loss industry's response to finally having to (at least begin to) admit that the Body Mass Index (BMI) is nonsense. The BMI is a ratio of weight and height that has been used to pathologize bodies based on their size alone and has its basis in racism. I talked about that in depth in this piece.Earlier this year the AMA, which takes hundreds of thousands of dollars in donations from the weight loss industry,  tried a little sleight of hand with this, admitting that there are serious issues with the BMI (which has been used as a justification for the much of the weight loss paradigm) but instead of acknowledging that simply pathologizing bodies based on shared size is an idea lacking scientific basis and merit that has done incredible harm, they instead said that we just needed more and different ways to pathologize bodies based on shared size.That brings us to the study Shauna sent me: “Body Roundness Index and All-Cause Mortality Among US Adults” published in JAMA (the Journal of the American Medical Association.)The authors reported no conflicts of interest, even though one of the authors, Qiushi Lin, MD, PhD, literally works for Sanofi Aventis which just had its weight loss drug preliminarily rejected by an FDA panel.Where the BMI is used to pathologize bodies based on weight and height, the The Body Roundness Index (BRI) uses weight and waist circumference.The specific calculation they used is “364.2 − 365.5 × √(1 − [waist circumference in centimeters / 2π]2 / [0.5 × height in meters]2)”The use of mathematical formulas tends to lend these concepts an heir of scientific validity that they do not deserve. They explain that “Due to the lack of a reference range, BRI was categorized into 5 groups according to the 20th, 40th, 60th, and 80th quantiles to explore the association with all-cause mortality.”They find a “U-shaped association between BRI and all-cause mortality. Our findings provide compelling evidence for the application of BRI as a noninvasive and easy to obtain screening tool for estimation of mortality risk and identification of high-risk individuals, a novel concept that could be incorporated into public health practice pending consistent validation in other independent studies.”By this they mean that those at the lower and higher ends of this scale have higher all-cause mortality. As I've talked about before, one of the cornerstones of research methods is that correlation does not imply causation. The U-shaped association they found might be a valid correlation. The mistake happens if the assumption is that the BRI is the REASON for the increased risk and, when it comes to weight and health (particularly those of higher-weight people) that's what typically happens. That's what I think the problem is going to be. In our culture, there is a tendency to jump at any perceived “proof,” no matter how shoddy, that being higher weight causes health issues/is a health issue. What these researchers have found is an unexplained correlation between being at lower and higher weights and higher rates of all-cause mortality. What they absolutely have not found is that being at lower and higher weight CAUSES higher rates of all cause mortality. They don't ever claim that they've found causation but then they conclude “a novel concept that could be incorporated into public health practice pending consistent validation in other independent studies” and not, for example, that causal mechanism(s) should be identified prior to foisting this formula on the public, it gives me the sense that they are jumping the gun here. I'm not going to do a deep dive into the methodology here because the concept is so deeply flawed at its base.I'll start with those at lower BRI range. Their BRI could be due to extreme illness (including everything from cancer, to substance use disorders, to eating disorders and more )that are the actual reason for increased all cause mortality. What they may have found is that those in the lower BRI categories are more likely to be very ill which means their findings would not extrapolate to those at the lower end of the weight spectrum who are not experiencing illness. When it comes to higher-weight people, we know that experiences of weight stigma, weight cycling, and healthcare inequalities are all associated with increased all-cause mortality. People with a higher BRI are more likely to have these experiences. Not only did these study authors fail to control for these, they failed to even mention them. Without controlling for these possible confounding variables, what their findings may indicate is just that they've found even more evidence that experiences of weight stigma, weight cycling, and healthcare inequalities increase all-cause mortality.So, if the lower someone's BRI category is, the more likely it is that they are very ill and the higher someone's BRI category is, the more likely that they've experienced/experience greater weight stigma, weight cycling, and healthcare inequalities, then we would see the exact “U-shaped association between BRI and all-cause mortality” that the study authors found.I'm not saying those are definitely the reasons, I'm saying that's the research we should be doing, not more research to reinforce a questionable correlation until the weight loss industry starts claiming that if there are *that many* studies that show correlation then it *must be* causation. Besides the weight loss industry (mis-)using this concept, I am worried about what this will lead to in terms of healthcare. The weigh-ins that patients are expected/pushed to endure in order to calculate BMI already cause some patients to delay or avoid healthcare appointments. How much worse is that going to become when healthcare providers are running after patients with tape measures to get a waist circumference measurement so they can calculate BRI. If BRI is “incorporated into public health practice” as these authors suggest using simply the correlation they've found, then the mostly likely outcome is that the suggestion is to manipulate BRI to improve all-cause mortality risk. This will be another way for the weight loss industry (including Sanofi Aventis if they can get their new drug into the endzone) to continue making money hand over fist, but for patients it will be the same old thing, which makes its use instead of BMI basically a distinction without a difference. Whether it's due to profit incentive, paradigm entrenchment, or a combination of both, the people doing this research seem to be willing to do absolutely anything other than control for confounding variables or consider the evidence that focusing on supporting health directly (rather than maintaining our obsession with weight loss,) may provide more benefits with fewer risks.Driven by the weight loss industry, weight science has gone a long way down the wrong road and they would rather step on the gas then slow down, let alone turn around. A healthcare system that is committed to viewing the existence of higher-weight people as a problem to be solved will never create polices or interventions that truly support the physical or mental health of higher-weight people. Did you find this post helpful? You can subscribe for free to get future posts delivered direct to your inbox, or choose a paid subscription to support the newsletter (and the work that goes into it!) and get special benefits! Click the Subscribe button below for details:Liked the piece? Share the piece!More research and resources:https://haeshealthsheets.com/resources/*Note on language: I use “fat” as a neutral descriptor as used by the fat activist community, I use “ob*se” and “overw*ight” to acknowledge that these are terms that were created to medicalize and pathologize fat bodies, with roots in racism and specifically anti-Blackness. Please read Sabrina Strings' Fearing the Black Body – the Racial Origins of Fat Phobia and Da'Shaun Harrison's Belly of the Beast: The Politics of Anti-Fatness as Anti-Blackness for more on this. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Could the secrets to perpetual youthfulness lie within our very genes? Dr. Gail Humble, a visionary in the realm of non-surgical aesthetic medicine, joins us to reveal her pioneering work on the Klotho gene and its impact on aging. With her extensive background in genetics, Dr. Humble argues that the way we age can be radically changed. Her conviction is clear: our outward appearance should be a reflection of our inner vitality. During our enthralling discussion, Dr. Humble offers a glimpse into her innovative products, ones that I've personally experienced, that harness the power of genetics to help preserve that inner spark.This episode also delves deep into the transformative power of a novel skincare technology. A protein cloak paired with liposome delivery works to fend off oxidative stress and enhance cellular longevity. Dr. Humble helps us understand how this technology not only protects skin from the sun's harmful rays but also fosters gene expression to fortify telomeres. The results speak for themselves, with noticeable improvements in skin texture, elasticity, and pigmentation becoming apparent in just a matter of weeks. We discuss the ease of integrating this technology into daily life and the striking before-and-after photos that stand as testament to this revolutionary approach.Join us for this fascinating episode where Dr. Humble sheds light on the intersection of wellness, technology, and the artful management of aging.About our Guest: Dr. Humble brings a commitment to perform the art and science of aesthetic medicine to its highest degree concentrating exclusively on non surgical procedures to enhance, mold, shape, and improve the face and body. Dr. Humble is originally from Northern California where she received her undergraduate degree in genetics from UC Davis. She received her medical degree from the University of Texas Medical Branch. Following a residency at USC, she received her boards in Anesthesia. Dr. Humble is a fellow of the Aesthetic Anti Aging Congress, and she is boarded by the American Board of Laser Medicine and Surgery. View NBC's Extra video clip featuring Dr Humble. videoShe is the author of multiple medical and non-medical articles as well as several medical journals, including Dermatologic Surgery and the Journal of Facial and Plastic Surgery. Many of the articles written by Dr. Humble are available in our Press section. She is a frequent lecturer at the World Congress of Anti Aging Medicine as well the Skin Disease and Education Foundation.Dr. Humble had one of the first non surgical cosmetic practices. She served as principle investigator of multiple studies on Sculptra and its use in revolumization. Dr. Humble has served as associate professor at USC, as well as a consultant and trainer to Allergan, Steifel, Galderma, Dermik, Sanofi-Aventis, Vaaleant, Lumenis and KMI.Dr. Humble believes that beauty is a reflection of the person inside. When we feel young and beautiful, or handsome, our image in the mirror should reflect that. She presently practices in both Northern and Southern California.https://klothoskin.com/Start Your ReLaunch Journey Today: https://therelaunchco.comInterested in being a guest on the ReLaunch Podcast or booking Hilary as a guest? Email UsFind Us on Your Favorite Podcast App -

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies Fluid restriction, bed rest, leg compression in acute heart failure Device-detected atrial fibrillation Snapshots  Host: Rick Grobbee Guests: Stephan Achenbach, Carlos Aguiar, Biykem Bozkurt and Paulus Kirchhof Want to watch that episode? Go to: https://esc365.escardio.org/event/1142 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Biykem Bozkurt has declared to have potential conflicts of interest to report: consulting for Abbott, Abiomed, American Regent, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Cardurion, Cytokinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva Nova, Merck, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, Vifor. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi, Novo Nordisk, Terumo, Medtronic. Paulus Kirchhof has declared to have potential conflicts of interest to report: fees from AstraZeneca, Roche Diagnostics, Johnson&Johnson, Philips, Medtronic, Boehringer-Ingelheim, Daiichi Sankyo. Research fundings from Sanofi Adventis, Abbott, German Ministry of Education and Research (BMBF), Daiichi Sankyo, British Heart Foundation, Leducq Foundation, European Union horizon2020, UK Medical Research Council and NIHR (UK National Institute of Health Research). Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/VQT865. CME/MOC/AAPA credit will be available until December 18, 2024.Beyond Airway Inflammation: Examining the Potential Clinical Utility of Mucus Plugging and Airway Hyperresponsiveness in Severe Asthma to Assess Severity and Guide Biologic Treatment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresCo-Chair/PlannerJonathan Corren, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Grant/Research Support from AstraZeneca; Novartis Pharmaceuticals Corporation; Regeneron Pharmaceuticals Inc.; and Sanofi.Speaker for AstraZeneca; Regeneron Pharmaceuticals Inc.; and Sanofi.Co-Chair/PlannerMario Castro, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Allakos Inc.; Amgen Inc.; Arrowhead Pharmaceuticals, Inc.; Genentech, Inc.; GSK; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; OM Pharma Ltd.; Pfizer; Pioneering Medicines; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Grant/Research Support from American Lung Association (ALA); AstraZeneca; Gala Therapeutics, Inc.; Genentech, Inc.; GSK; National Institutes of Health (NIH); Novartis Pharmaceuticals Corporation; Patient-Centered Outcomes Research Institute (PCORI); Pulmatrix, Inc.; Sanofi-Aventis; Shionogi & Co., Ltd; and Theravance Biopharma.Speaker for Amgen Inc.; AstraZeneca; Genentech, Inc.; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis; and Teva Pharmaceuticals USA, Inc.Stock Shareholder in Aer Therapeutics.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Damjanovich Nebojsa Szabadkán született, tanulmányait részben ott, részben pedig Budapesten folytatta, 1993 óta él Magyarországon és itt tanulta meg a magyar nyelvet. 1995-ben a Szegedi Mozaik alapítója és kiadója, 1998-ban a VNU majd Sanoma értékesítési menedzsere, 1999-től 2001-ig a MediaCom médiatervezője.2001 óta digitális marketing tanácsadóként és trénerként tevékenykedik, melyből 3 évet multinacionális cégeknél töltött, mint például a Grey Budapest és az Allegroup.hu (Vatera). Őszinteségének, szakmaiságának és személyiségének köszönhetően számos ismert ügyfele volt az elmúlt 20 évben: Microsoft, Magyar Telekom, Vodafone, NOKIA, Raiffeisen Bank, OTP Bank, Aegon, Allianz, CLB, Netrisk.hu, Sanofi-Aventis, Merck, MSD, GlaxoSmithKline, Bayer, Richter Gedeon, Teva Magyarország, AstraZeneca, Lilly, Sodexo, GE Lighting, DHL, UPC Air France, Office Depot, Syngenta, Schibsted, Sanoma Budapest, Inform Média, Lapcom. A Resend Agency B2B marketing ügynökségével dolgoznak hazai és azon kívül Kanadai, Szlovákiai, Bulgáriai, Lengyelországi, Szlovéniai és Szerbiai cégeknek is. Évente legalább 10 konferencián szerepel előadóként marketinggel kapcsolatban, továbbá vendégelőadó az Edutus és Corvinus Egyetemeken, több cikk és könyv is fűződik a nevéhez. --- Tudjon meg többet Damjanovich Nebojsá - ról. --- Nézd meg ennek a podcast-epizódnak a videó változatát: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/magyar-business-podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Iratkozz fel a - sallang mentes - havi hírlevelünkre: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/Hirlevel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Hallgasd meg es iratkozz fel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/MBP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Magyar Business Podcastről: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/MBP⁠⁠⁠⁠⁠

Damjanovich Nebojsa Szabadkán született, tanulmányait részben ott, részben pedig Budapesten folytatta, 1993 óta él Magyarországon és itt tanulta meg a magyar nyelvet. 1995-ben a Szegedi Mozaik alapítója és kiadója, 1998-ban a VNU majd Sanoma értékesítési menedzsere, 1999-től 2001-ig a MediaCom médiatervezője.2001 óta digitális marketing tanácsadóként és trénerként tevékenykedik, melyből 3 évet multinacionális cégeknél töltött, mint például a Grey Budapest és az Allegroup.hu (Vatera). Őszinteségének, szakmaiságának és személyiségének köszönhetően számos ismert ügyfele volt az elmúlt 20 évben: Microsoft, Magyar Telekom, Vodafone, NOKIA, Raiffeisen Bank, OTP Bank, Aegon, Allianz, CLB, Netrisk.hu, Sanofi-Aventis, Merck, MSD, GlaxoSmithKline, Bayer, Richter Gedeon, Teva Magyarország, AstraZeneca, Lilly, Sodexo, GE Lighting, DHL, UPC Air France, Office Depot, Syngenta, Schibsted, Sanoma Budapest, Inform Média, Lapcom. A Resend Agency B2B marketing ügynökségével dolgoznak hazai és azon kívül Kanadai, Szlovákiai, Bulgáriai, Lengyelországi, Szlovéniai és Szerbiai cégeknek is. Évente legalább 10 konferencián szerepel előadóként marketinggel kapcsolatban, továbbá vendégelőadó az Edutus és Corvinus Egyetemeken, több cikk és könyv is fűződik a nevéhez. --- Nézd meg ennek a podcast-epizódnak a videó változatát: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/magyar-business-podcast⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Iratkozz fel a - sallang mentes - havi hírlevelünkre: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/Hirlevel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Hallgasd meg es iratkozz fel: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/MBP⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ --- Magyar Business Podcastről: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://www.magyarbusiness.org/MBP⁠⁠⁠⁠⁠

Henrico County has filed a federal lawsuit against three manufacturers of insulin, three pharmacy benefit managers, and 12 subsidiaries of the companies, alleging that they conspired to artificially inflate the price of the medicine, which is used to treat diabetes. In the suit, filed Nov. 20 in the U.S. District Court for the Eastern District of Virginia, Henrico alleges that insulin manufacturers Eli Lilly and Company, Novo Nordisk Inc. and Sanofi-Aventis, U.S., LLC and pharmacy benefit managers CVS Caremark, Express Scripts and OptumRx, and their subsidiaries, “have in tandem increased the prices of their insulins up to 1000%,” during the...Article LinkSupport the show

Karius' story is all about equipping doctors with the right information, for the right patient, at the right time. For most immunocompromised patients, it's a matter (quite literally) of life or death.  When Alec Ford's daughter was just a toddler, she suffered with asthma and caught a viral infection that led to secondary bacterial infections and was hospitalized multiple times. Alec says he watched doctors try to help his daughter, but the tools they had to figure out exactly how to provide the best anti-infective care for her were all a failure. “They couldn't find the cause, they'd get the antibiotic wrong. I held her hand as they put her to sleep through multiple bronchoscopies, which as a new parent, you can imagine, just terrifies you to no end,” Alec says. “That's why I'm at this company. It was this chance to be a part of changing something that was very personal to me.”   Alec, who graduated from Stanford University and has more than 30 years of experience at top biopharma companies, including Pfizer, Sanofi-Aventis, Novartis, Nektar Therapeutics, and Myriad Genetics, is now CEO of ⁠Karius⁠. Karius developed the trademarked ⁠Karius Test⁠, a non-invasive liquid biopsy that can identify more than ⁠1,500 pathogens⁠—including the monkeypox virus—and helps clinicians identify the source of an infection in an immunocompromised patient, such as people who have cancer. Alec says that out of the 630,000 or so cancer deaths that occur every year in the U.S., over half of them are actually due to infection.   Karius recently raised $165 million from a Series B funding round and was recently named to the Forbes AI 50, a list of the most promising artificial intelligence companies.  You can follow Alec Ford and Karius on ⁠LinkedIn⁠. LifeLines is produced by Biocom California, the leader and advocate for life science in California and beyond. To learn more about us, visit ⁠biocom.org⁠ or engage with us on ⁠Twitter⁠ and ⁠LinkedIn⁠. For a transcript of this episode, you can download it ⁠here.⁠ Interested in becoming a member or joining us on this podcast? Email ⁠podcast@biocom.org⁠.  Host: Chris Conner  Executive Producer: Marie Tutko  Senior Producer: Vincenzo Tarantino  Associate Producer: Lauren Panetta  Program & Research Coordinator: Katy Burgess  Transcripts By: Jessica Schneider   Senior Director of Marketing: Heather Ramsay  Graphic Design By: Raquel Papike 

The Business of Meetings – Episode 146 - From Corporate to Convention Bureau with Christoph Tessmar Today we have the great pleasure of speaking with Christoph Tessmar, the Director of the Barcelona Convention Bureau!  Christoph is well-known all over the world in the meetings and events industry. He has had an incredible journey, from pharmaceuticals to events to becoming the head of the Barcelona Convention Bureau. He joins us today to discuss his journey and to share many fascinating stories! We hope you enjoy listening to today's inspiring conversation with Christoph Tessmar! Bio: Christoph Tessmar was born in Heidelberg (Germany) on the 3rd of May 1964. After his education, he started his professional career (always in the pharmaceutical industry) in Boehringer Mannheim as an area manager for some countries in South America. In January 1990, he moved to Boehringer Mannheim in Barcelona, where he started with the organization of some events and congresses. In 1999, he joined Sanofi-Aventis Spain, as congress manager. He was in charge of the organization and coordination of all the events of the company (national and international congresses, product presentations, symposia, sales conventions, and booth design) nearly 500 events per year, where he worked until January 2012. Since March 2012, he has been the Director of the Barcelona Convention Bureau. Since April 2019, he has been president of the ICCA Iberian Chapter and a member of the PCMA European Advisory Board. Christoph's story Christoph started his career working for a pharmaceutical company in Germany while he was still studying back in 1981. In 1989, he went to Barcelona to work with an affiliate company. He liked it so much that he asked for a permanent position there. He was offered a job on the salesforce and had to go out selling to gain experience. The marketing manager contacted him saying they had a new product to launch, and asked him to help them organize an event in Berlin. The event was a success! As the company grew, he was asked to do more events. In 1998, the company was sold, and he had to leave. He then received an offer from Sanofi-Aventis in Spain to create a congress department. He remained with that company until he joined the Barcelona Convention Bureau in 2012.  The Barcelona Convention Bureau As someone from the corporate world, Christoph felt challenged when he was asked to join the Barcelona Convention Bureau, but he accepted the position because it was a chance for him to do something new and different.  Gaining trust Christoph gained the trust of those he had to represent because he was known to be open and present as a Congress Manager in the meetings industry. The Convention Bureau is within the DMO of the Barcelona Tourism Board. He was known by many people who had confidence in his ability, and they welcomed him happily. The Barcelona Football Club The Barcelona Football Club was a member of the Barcelona Convention Bureau. However, the membership is frozen while the stadium goes through a four to five-year process of reconstruction and renovation. Unexpected crises There have been many attacks, riots, and crises in Barcelona since 2014. The Barcelona Convention Bureau managed to get through all of the unexpected crises, including Covid.                                     Fortunately, Christoph has developed a good relationship with the police over the years, and they have been very helpful. When something important is about to happen in the city, the Convention Bureau forms a security committee, including the police, to plan and prepare in case something unforeseen occurs. Cancellation policies Since the pandemic, many cancellation policies in Barcelona have changed because clients have asked to cancel with a shorter notice period.   IBTM  Christoph recently closed one of the best and most successful IBTMs he has experienced in all his years with the Convention Bureau. He was surprised by how successful it was because he had no idea what would happen or how many buyers, visitors, and exhibitors would be there. They have subsequently signed a contract to have IBTMs (Incentives, Business Travel & Meetings) in the city for three more years. ICCA ICCA organized an event for students considering careers in the meetings industry. Three or four ICCA members will explain what they do, share insights about the industry, and answer questions, to convince the students to join the industry because the meetings and events industry needs new talent. The benefits of volunteering Christoph has found volunteering a way to bring his experience into various associations, open people's minds, and help them change and adapt. Connect with Eric On LinkedIn On Facebook On Instagram On Website Connect with Christoph Tessmar On LinkedIn Barcelona Convention Bureau